{
    "root": "23bbd301-54b0-447b-93c1-a6ff1e13ce4f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ARBLI",
    "value": "20250320",
    "ingredients": [
        {
            "name": "LOSARTAN POTASSIUM",
            "code": "3ST302B24A"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T"
        },
        {
            "name": "PROPYLPARABEN",
            "code": "Z8IX2SC1OH"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "DIMETHICONE",
            "code": "92RU3N3Y1O"
        },
        {
            "name": "SUCRALOSE",
            "code": "96K6UQ3ZD4"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC",
            "code": "GR686LBA74"
        },
        {
            "name": "SODIUM PHOSPHATE, MONOBASIC",
            "code": "3980JIH2SW"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        }
    ],
    "indications": "Arbli is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 )",
    "contraindications": "Hypertension Usual adult dose: 50 mg orally once daily. ( 2.2 ) Usual pediatric starting dose: 0.7 mg per kg orally once daily (up to 50 mg). ( 2.2 ) Hypertensive Patients with Left Ventricular Hypertrophy Usual starting dose: 50 mg orally once daily. ( 2.3 ) Add hydrochlorothiazide 12.5 mg and/or increase Arbli to 100 mg orally followed by an increase to hydrochlorothiazide 25 mg if further blood pressure response is needed. ( 2.3 , 14.2 ) Nephropathy in Type 2 Diabetic Patients Usual dose: 50 mg orally once daily. ( 2.4 ) Increase dose to 100 mg orally once daily if further blood pressure response is needed. ( 2.4 )",
    "warningsAndPrecautions": "Arbli (losartan potassium)is a white, translucent oral suspension. Each mL contains 10 mg losartan potassium (equivalent to 9.2 mg losartan).  It is supplied as 165 mL in a high-density polyethylene (HDPE) bottle with a child-resistant cap and tamper-evident seal. Shake for 20 seconds prior to each use. \n                  NDC 83245-053-06\n                  Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Keep container tightly closed. Protect from light.\n                  Store and dispense in original container. Once the bottle is opened, use it within 60 days.",
    "adverseReactions": "Arbli is contraindicated:\n                  \n                     In patients who are hypersensitive to any component of this product.\n                     For co-administration with aliskiren in patients with diabetes."
}